Billiontoone, Inc. (NASDAQ:BLLN – Free Report) – Stock analysts at William Blair issued their Q3 2025 earnings estimates for Billiontoone in a research report issued on Monday, December 1st. William Blair analyst A. Brackmann forecasts that the company will post earnings of $0.14 per share for the quarter. William Blair has a “Outperform” rating on the stock. William Blair also issued estimates for Billiontoone’s Q4 2025 earnings at ($0.10) EPS, FY2025 earnings at ($0.04) EPS, Q1 2026 earnings at ($0.08) EPS, Q2 2026 earnings at ($0.02) EPS, Q3 2026 earnings at $0.05 EPS, Q4 2026 earnings at $0.04 EPS, FY2026 earnings at $0.00 EPS, FY2027 earnings at $0.51 EPS and FY2028 earnings at $1.42 EPS.
A number of other analysts also recently commented on the company. Jefferies Financial Group initiated coverage on Billiontoone in a research note on Monday. They issued a “hold” rating and a $117.00 target price on the stock. Zacks Research upgraded Billiontoone to a “hold” rating in a research report on Tuesday. Wells Fargo & Company started coverage on shares of Billiontoone in a report on Monday. They set an “equal weight” rating and a $110.00 target price for the company. JPMorgan Chase & Co. assumed coverage on shares of Billiontoone in a report on Monday. They set an “overweight” rating and a $150.00 price target on the stock. Finally, Stifel Nicolaus initiated coverage on shares of Billiontoone in a research report on Monday. They set a “buy” rating and a $145.00 price target on the stock. Five investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, Billiontoone has an average rating of “Moderate Buy” and a consensus target price of $138.67.
Billiontoone Stock Performance
Shares of BLLN opened at $104.02 on Wednesday. Billiontoone has a fifty-two week low of $88.00 and a fifty-two week high of $138.70.
About Billiontoone
BillionToOne is transforming healthcare by redefining molecular diagnostics. Our revolutionary single molecule NGS (smNGS) platform achieves what was once thought impossible – detecting and precisely quantifying genetic targets with single-molecule sensitivity. At the heart of this technological breakthrough lies our patented QCTs, enabling measurements at the physical limit of detection – the single DNA molecule.
Featured Stories
- Five stocks we like better than Billiontoone
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- The Trade Desk: After a 70% Plunge, This Could Be The Time to Buy
- How to Calculate Stock Profit
- Tap Into 2026 AI Infrastructure Gains With This High-Growth ETF
- How to Choose Top Rated Stocks
- Strong Quarter, Weak Reaction: Why GitLab Shares Dropped
Receive News & Ratings for Billiontoone Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Billiontoone and related companies with MarketBeat.com's FREE daily email newsletter.
